data for <b>The role of Orai 3 and HV1 in regulating B cell receptor (BCR) signaling and cell progression of high-grade B cell lymphoma (HGBL) cell lines</b>

<br>- Organism: All cell lines are derived from Human - Developmental Stage: All samples are at the maturation stage.- Genotype: All are from male (XY) individuals.- Sample Diversity:- Sample 1 represents normal B cells from blood with a specific antibody deficiency but normal immunoglobulin and B cell counts.- Samples 2, 3, and 4: SU-DHL4, CS-THL1, and DOGKIT are B-cell non-Hodgkin lymphoma cell lines from different anatomical sites (peritoneal cavity, lymphoid tissue, and EBV-negative Burkitt lymphoma, respectively).- Material Type: RNA extracted from each sample.- Library Preparation: All libraries are single-end, prepared via RT-PCR, with a transcriptomic strategy and first-strand synthesis.- Assay and Technology: Sequencing assays were performed for transcriptomic profiling.- Disease Context: Samples 2–4: Lymphoid system diseases, specifically B-cell non-Hodgkin lymphomas.<br>

- 生物来源：所有细胞系均来源于人（Human）
- 发育阶段：所有样本均处于成熟阶段
- 基因型：所有样本均取自男性（XY染色体型）个体
- 样本多样性：
- 样本1为血液来源的正常B细胞，存在特定抗体缺陷，但免疫球蛋白水平与B细胞计数均正常
- 样本2、3、4分别为SU-DHL4、CS-THL1和DOGKIT细胞系，均为源自不同解剖部位的B细胞非霍奇金淋巴瘤细胞系：其中SU-DHL4取自腹腔，CS-THL1取自淋巴组织，DOGKIT为EB病毒（EBV）阴性的伯基特淋巴瘤细胞系
- 样本材料类型：各样本提取的RNA（RNA）
- 文库构建：所有文库均为单端（single-end）文库，通过逆转录聚合酶链式反应（RT-PCR）构建，采用转录组学策略并完成第一链合成
- 检测技术与实验方法：采用测序检测开展转录组分析
- 疾病背景：样本2至4对应的疾病为淋巴系统疾病，具体为B细胞非霍奇金淋巴瘤